Tech Company Financing Transactions
Peptilogics Funding Round
Presight Capital, Founders Fund and private investors participated in a $35.4 million Series B funding round for Peptilogics. This venture round was announced on 12/23/2020.
Transaction Overview
Company Name
Announced On
12/23/2020
Transaction Type
Venture Equity
Amount
$35,400,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to expand its computational platform and invest in technologies to improve its drug design engine, as well as accelerate development of a pipeline of peptide therapeutics including the lead clinical asset, PLG0206, which has demonstrated first-in-class safety and best-in-class efficacy.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2730 Sidney St. 300
Pittsburgh, PA 15203
USA
Pittsburgh, PA 15203
USA
Phone
Undisclosed
Website
Email Address
Overview
Peptilogics is an early-stage biotechnology company utilizing an innovative platform technology which enables us to rapidly and effectively develop novel peptide therapeutics, with a focus on antibiotics. Our pipeline includes a novel class of engineered Cationic Antimicrobial Peptides (eCAPs).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Sanjay Kakkar
Chief Medical Officer
Todd Lorenz
Chief Scientific Officer
Jonathan Steckbeck
Browse more venture capital transactions:
Prev: 12/23/2020: Atriomx Health venture capital transaction
Next: 12/23/2020: Ironclad venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to record funding rounds that are announced publicly. VC investment data records reported here are derived from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs